Polivy (polatuzumab vedotin-piiq)

How It Works

Polivy works by combining a monoclonal antibody with a chemotherapy drug. The monoclonal antibody component of Polivy specifically binds to CD79b, a protein found on the surface of B-cells. Once bound, the drug is internalized by the cell, where the attached chemotherapy agent, monomethyl auristatin E (MMAE), is released. MMAE disrupts the microtubule network within the cancer cell, which is essential for cell division, ultimately leading to cell death.

Side Effects

• Peripheral neuropathy
• Neutropenia (low white blood cell count)
• Anemia
• Thrombocytopenia (low platelet count)
• Fatigue
• Nausea
• Diarrhea
• Fever
• Decreased appetite
• Upper respiratory tract infection

Indications

• Diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and rituximab, for patients who have not responded to or have relapsed after at least two prior therapies

Contraindications

• Hypersensitivity to polatuzumab vedotin or any of its components
• Severe liver impairment
• Patients with active, uncontrolled infections

Price Comparison in Different Countries

Top 5 Global Brands

1. Novartis
2. Pfizer
3. Roche
4. Sanofi
5. GlaxoSmithKline (GSK)

Conclusion

Polivy (polatuzumab vedotin-piiq) is a significant therapeutic option for patients with diffuse large B-cell lymphoma (DLBCL) who have not responded to or have relapsed after previous treatments. By targeting the CD79b protein on B-cells, Polivy delivers a potent chemotherapy agent directly to the cancer cells, enhancing treatment efficacy while minimizing systemic exposure. Patients should be aware of potential side effects and contraindications, and discuss these with their healthcare provider. The cost of Polivy varies significantly across different countries, reflecting differences in healthcare systems and pricing strategies. Patients should explore financial assistance programs and consult their healthcare providers to understand the best options available to them.